Trim 20-25% to 75-80% residual; $375 hard stop, full exit below $349.61 weekly close
The 20-25% trim to 75-80% residual is the optimal sizing per the 09-14 binding reflection, which explicitly directs heavier sizing when technical breakdown AND fundamental deterioration converge simultaneously. This positioning sits outside every documented failure zone: lighter than the 09-04 (55-60% trim) and trader's proposal (50-70%) to preserve franchise optionality if Q3 confirms recovery; heavier than the 09-14 (10-15% trim) to properly monetize converging deterioration into positive alpha. Full Sell is avoided given load-bearing franchise floor evidence ($24B+ TTM FCF, A-rated balance sheet, $28.6B cash, 0.62 beta, 200 SMA at $351). The residual captures upside if Q3 confirms recovery and technical damage resolves as coiled-spring exhaustion; captures meaningful alpha with $375 stop protection if Q3 disappoints and floor fails.
| Position | Action |
|---|---|
| Current position → trim 20-25% | Leave 75-80% residual |
| Bear downgrade triggers (close below $375 on volume OR weekly close below $349.61 OR Q3 EPS <$5.50 OR guidance cut) | Additional 30% trim → 50% residual plus defensive puts on residual |
| Weekly close below $349.61 | Full exit to 0% position, no waiting for confirmation |
A cyclical medical cost trough, not structural impairment, has created a historic entry point in UNH — trading at 14.5x P/E on normalized $24+ annualized earnings versus a 5-year average of 20-22x, with a fortress balance sheet generating $24.3B in trailing FCF, a 2.42% dividend yield with 16 consecutive years of dividend growth, and a wide competitive moat serving 50M+ Americans — making this a BUY at $375.93 with 15-25% upside to $425-450.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 349.31 | bullish |
| close_50_sma | 405.09 | bearish |
| close_10_ema | 386.44 | bearish |
| rsi | 37.32 | bearish |
| macd | -5.55 | bearish |
| macd_histogram | -1.08 | bearish |
| boll_middle | 390.13 | neutral |
| boll_upper | 403.80 | neutral |
| boll_lower | 376.46 | neutral |
| atr | 10.54 | neutral |
| vwma | 390.46 | bearish |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: (a) UNH trades at ≤20x TTM earnings, OR (b) two consecutive quarters of stable Optum Health margin trajectory, OR (c) 10Y yield falls below 4.5%, OR (d) confirmed close above $408.33 with MACD positive and RSI >50
Then: Begin adding back to Overweight
UNH's cash flow generation is exceptional even through the trough quarter
EV: +15-25% · concedes: The FOMC decision on September 16 could create near-term headwinds if the 88% Polymarket hike probability materializes, causing brief sideways to downward pressure; The October 1 prior-auth removal and Q3 2026 earnings will be the true validation points for the normalization thesis; A stop below the 200-day MA at $340 limits downside to approximately 9% if the thesis fails
UNH is a "quality at a cyclical trough" value trap—the Q4 2025 earnings reset signals structurally broken economics, not a temporary blip, with the inputs that caused it (MA payment pressure + rising care costs) worsening rather than improving, while a hostile macro environment (5% 10-year, 88% Fed hike probability) mechanically compresses multiples for the entire defensive-duration cohort.
· concedes: $4.4B net debt repayment in Q2 2026 was a meaningful positive; Q1-Q2 2026 showed some earnings recovery from the Q4 2025 trough; Long-term structural tailwinds (AI, prior-auth reform) exist but won't materialize until 2027+; Q1/Q2 2026 MLR was favorable but Q3+ headwinds grow
→ vs conservative: The 14.5x forward P/E is not a 'statistical artifact' — stripping out Q4 2025's abnormal claims spike shows normalized earnings at 16-17x, a 25% discount to the five-year average, which is cheap rather than fairly valued
→ vs conservative: The three quarters of zero buybacks, framed as bearish management hesitation, actually preceded a massive $1.65 billion Q2 2026 buyback — management behavior signals they view $375 as attractive, not fair value
→ vs conservative: The 'wall' and 'reset' framing is not evidence of weakness but evidence of good operational execution — confronting reality, taking charges, and repositioning (WellMed TPG partnership, 1,700 prior-auth cuts) is exactly what drives margin recovery in 2027-2028
→ vs conservative: Rising rates and hawkish Fed create a hostile backdrop is backwards — defensive healthcare stocks with 0.62 beta are precisely what outperforms in hawkish regimes; the correlation between rising rates and healthcare breakdown is not as clean as assumed
→ vs conservative: The $130 billion goodwill with negative tangible book value is meaningless for a company generating $24 billion in annual free cash flow — the market doesn't mark down insurers unless there's a solvency concern, and there is none here
Support: 376 · 349 · 326 · 336 · 274 · 253 | Resistance: 374 · 376 · 386.44 · 390 · 403.8 · 405.09 · 412 · 415
UNH exhibits a bifurcated technical picture: bearish signals dominate short- and medium-term timeframes (price below 10 EMA, 50 SMA, and VWMA; negative and widening MACD histogram; declining short-term trend), while the long-term uptrend remains technically intact with price still 7.6% above the 200 SMA at 349.31. RSI at 37.32 has room to decline further before reaching oversold territory, but the lower Bollinger Band at 376.46 was tested intraday, historically a near-term exhaustion signal. ATR of 10.54 reflects elevated volatility requiring wider stop-loss placement. VWMA declining steadily from ~$425 to $390.46 suggests methodical institutional distribution rather than panic selling. Key support lies at 376 (today's low), 349 (200 SMA), and 326-336 (late-2025 consolidation zone), while resistance sits at 390 (VWMA/lower Bollinger), 405 (50 SMA), and 412-415 (late-August pivot). The rating is HOLD.
Market Cap
$337.4 B
P/E (TTM)
24.1x
Forward P/E
16.7x
PEG Ratio
1.04
Price / Book
3.46x
EPS (TTM)
$15.57
Forward EPS
$22.55
Book Value
$108.78
Dividend Yield
2.42%
Revenue (TTM)
$450.5 B
Gross Profit (TTM)
$88.9 B
EBITDA (TTM)
$26.7 B
Net Income (TTM)
$14.1 B
Operating Margin (TTM)
7.13%
Net Margin (TTM)
3.14%
ROE (TTM)
14.15%
ROA (TTM)
4.87%
Free Cash Flow (TTM)
$24.3 B
Total Assets (Q2 2026)
$309.7 B
Total Debt (Q2 2026)
$73.3 B
Cash & ST Investments (Q2 2026)
$31.5 B
Net Debt (Q2 2026)
$44.7 B
Stockholders' Equity (Q2 2026)
$98.4 B
Debt-to-Equity (Q2 2026)
69.21
Current Ratio (Q2 2026)
0.78
Tangible Book Value (Q2 2026)
-$31.9 B
Goodwill (Q2 2026)
$110.6 B
Other Intangibles (Q2 2026)
$19.7 B
Beta
0.622
52-Week High
$461.62
52-Week Low
$255.97
50-Day MA
$408.33
200-Day MA
$353.35
Q2 2026 EPS
$6.04
Q1 2026 EPS
$6.90
Q4 2025 EPS
$0.01
Q3 2025 EPS
$2.59
Q2 2025 EPS
$3.74
Q2 2026 Revenue
$112,032 M
Q2 2026 Gross Profit
$23,299 M
Q2 2026 Operating Income
$7,991 M
Q2 2026 EBITDA
$8,970 M
Q2 2026 Net Income
$5,484 M
Q2 2026 Operating Cash Flow
$11,052 M
Q2 2026 Free Cash Flow
$10,253 M
Q2 2026 CapEx
$799 M
Strengths
Concerns
UnitedHealth Group (UNH) is the largest U.S. diversified healthcare company operating through UnitedHealthcare (insurance/managed care serving 50M+ Americans) and Optum (health services, pharmacy benefit management, and data analytics). The company experienced a significant earnings event in Q4 2025 (net income of just $10M, EPS of $0.01) due to a medical cost spike, but has shown sharp recovery in H1 2026 with EPS of $6.90 (Q1) and $6.04 (Q2). The company generates exceptional free cash flow (~$24.3B TTM) and is actively deleveraging, with net debt falling from $54.0B to $44.7B over two quarters. The wide valuation gap between TTM P/E of 24.1x and Forward P/E of 16.7x indicates the market is pricing in normalized earnings recovery, with the stock currently trading between its 50-day ($408.33) and 200-day ($353.35) moving averages.
Macro: The macro regime has shifted from "soft landing + cuts" to "reflationary + hiking" in the span of one week. The 10-year Treasury hit its highest level since 2007, briefly piercing 5%. Oil pushed above $100/barrel. Polymarket is pricing an 88% probability of a +25 bps Fed hike at the September 16 FOMC meeting—a dramatic swing with a +33pp one-week swing toward hike. US recession odds by end-2026 rose to 23% (+15.5pp on the week). Treasury unveiled $6B bond buybacks with marginal liquidity backstop, but long-end yields remain elevated. Tech/semis sold off with AI-capex narrative re-priced lower. This hawkish shift is the dominant driver of risk-asset pricing and overrides company-specific bullish news in the near term.